摘要
糖尿病是世界范围内主要的死亡原因之一。胰腺β-细胞、胰岛实质细胞的丢失和功能衰竭,进展为糖尿病。这,这个,那,那个这种代谢紊乱的发病率增加,需要有效的策略来产生功能β-细胞来治疗糖尿病。人诱导多能干细胞(HiPSC)TiAl用于治疗糖尿病,使其具有自我更新的能力和分化为β细胞的能力。iscc技术还提供无限的起始材料来产生分化细胞。用于再生应用的LS。在建立体外培养程序以通过不同的Re产生确定的内胚层、胰腺内胚层祖细胞和β-细胞方面也取得了进展。方案编制战略和增长因子补充。然而,这些产生的β-细胞仍不成熟,缺乏功能特征,在逆转疾病方面表现出较低的能力。editions版次( edition的名词复数 ) 目前用于产生成熟功能的β细胞的方法包括:利用小分子和大分子来提高重编程和分化效率,提高三维培养系统的效率。分化细胞的功能特性和异质性。 本综述详细介绍了最近通过将干细胞重新编程成β,进而被编程为β-细胞来生成成熟的β-细胞方面的进展。它还能更深入地了解当前的情况。重新编写协议及其有效性,重点讨论基于化学的方法生成IPSCs的基本机制。此外,我们还强调了最近的差异化战略。TH在体内和体外培养成熟的β-细胞,并展望其未来的发展前景.
关键词: 糖尿病,化学基础重编程,胚胎干细胞,诱导多能干细胞,小分子和大分子,成熟胰岛素产生β-细胞。
图形摘要
Current Drug Targets
Title:Advances in the Generation of Functional β-cells from Induced Pluripotent Stem Cells As a Cure for Diabetes Mellitus
Volume: 19 Issue: 13
关键词: 糖尿病,化学基础重编程,胚胎干细胞,诱导多能干细胞,小分子和大分子,成熟胰岛素产生β-细胞。
摘要: Diabetes mellitus is one of the leading causes of death worldwide. Loss and functional failure of pancreatic β-cells, the parenchyma cells in the islets of Langerhans, progress diabetes mellitus. The increasing incidence of this metabolic disorder necessitates efficient strategies to produce functional β-cells for treating diabetes mellitus. Human induced Pluripotent Stem Cells (hiPSC), hold potential for treating diabetes ownig to their self-renewal capacity and the ability to differentiate into β- cells. iPSC technology also provides unlimited starting material to generate differentiated cells for regenerative applications. Progress has also been made in establishing in-vitro culture protocols to yield definitive endoderm, pancreatic endoderm progenitor cells and β-cells via different reprogramming strategies and growth factor supplementation. However, these generated β-cells are still immature, lack functional characteristics and exhibit lower capability in reversing the diseases conditions.
Current methods employed to generate mature and functional β-cells include; use of small and large molecules to enhance the reprogramming and differentiation efficiency, 3D culture systems to improve the functional properties and heterogeneity of differentiated cells.
This review details recent advancements in the generation of mature β-cells by reprogramming stem cells into iPSCs that are further programmed to β-cells. It also provides deeper insight into current reprogramming protocols and their efficacy, focusing on the underlying mechanism of chemical-based approach to generate iPSCs. Furthermore, we have highlighted the recent differentiation strategies both in-vitro and in-vivo to date and the future prospects in the generation of mature β-cells.
Export Options
About this article
Cite this article as:
Advances in the Generation of Functional β-cells from Induced Pluripotent Stem Cells As a Cure for Diabetes Mellitus, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180605112917
DOI https://dx.doi.org/10.2174/1389450119666180605112917 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Autologous Circulating Progenitor Cells Transplanted with Hybrid Scaffold Accelerate Diabetic Wound Healing in Rabbit Model
Current Tissue Engineering (Discontinued) Heart Failure in Diabetes Mellitus: An Updated Review
Current Pharmaceutical Design Inflammasomes in the Pathophysiology of Maternal Obesity: Potential Therapeutic Targets to Reduce Long-Term Adverse Health Outcomes in the Mother and Offspring
Current Vascular Pharmacology Prenatal Care for Women with Schizophrenia
Current Women`s Health Reviews Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clinical Presentation, Diagnostic Work-Up, and Treatment of Coronary In-Stent Restenosis
Vascular Disease Prevention (Discontinued) Establishing Maternal Tolerance: The Role of Regulatory T Cells (Tregs) in Pregnancy and Pathophysiology of Preeclampsia
Current Women`s Health Reviews Diabetic Vasculopathy and the Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 (LOX-1)
Current Diabetes Reviews The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Impact of Endothelial NOS VNTR Variant on Susceptibility to Diabetic Neuropathy and Type 2 Diabetes Mellitus
Current Neurovascular Research Understanding the Mechanism and Prevention of Arterial Occlusive Thrombus Formation by Anti-Platelet Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting Metabolic Enzymes in Cancer – Clinical Trials Update
Current Enzyme Inhibition Hypovitaminosis D is Associated with Endothelial Dysfunction in Patients with Metabolic Syndrome
Current Vascular Pharmacology Drugs for AIDS
Mini-Reviews in Medicinal Chemistry From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Effects of Vitamin C and E Against Oxidative Stress: Is Antioxidant Supplementation Efficient?
Current Nutraceuticals Editorial [Innovative Therapeutic Approaches for the Treatment of Pediatric Autoimmune and Inflammatory Diseases Executive (Guest Editor: Giorgio Zauli)]
Current Pharmaceutical Design Incidence and Risk Factors for Tenofovir-Associated Renal Function Decline Among Thai HIV-Infected Patients with Low-Body Weight
Current HIV Research Neonatal Diabetes: Applying Molecular Biology to Patient Care
Current Pediatric Reviews Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology